SCHEMBL9969411

SCHEMBL9969411

C[C@H]([C@@H](O)c1ccccc1)C(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.57
KDM4E B2RXH2 3/20 0.56
ADRA2C P18825 2/20 0.56
LMNA P02545 2/20 0.56
ADRA2A P08913 1/20 0.56
HIF1A Q16665 1/20 0.56
ALDH1A1 P00352 3/20 0.54
CHRM2 P08172 1/20 0.52
ADRA1A P35348 1/20 0.52
RGS12 O14924 1/20 0.52
GLA P06280 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
PKM P14618 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
ALOX12 P18054 1/20 0.52
NFKB1 P19838 1/20 0.52
HTR2A P28223 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9969410 1.00 SLC6A4 (0.57) SLC6A4KDM4EADRA2CLMNAADRA2A
SCHEMBL12435659 1.00 SLC6A4 (0.57) SLC6A4KDM4EADRA2CLMNAADRA2A
SCHEMBL15426322 1.00 SLC6A4 (0.57) SLC6A4KDM4EADRA2CLMNAADRA2A
SCHEMBL14357378 1.00 SLC6A4 (0.57) SLC6A4KDM4EADRA2CLMNAADRA2A
SCHEMBL12939631 1.00 SLC6A4 (0.57) SLC6A4KDM4EADRA2CLMNAADRA2A
SCHEMBL14357099 1.00 SLC6A4 (0.57) SLC6A4KDM4EADRA2CLMNAADRA2A
SCHEMBL22810963 0.83 SLC6A4 (0.53) SLC6A4KDM4EADRA2CLMNAADRA2A
SCHEMBL1961679 0.80 KDM4E (0.65) SLC6A4KDM4EADRA2CLMNAADRA2A
SCHEMBL765762 0.80 KDM4E (0.65) SLC6A4KDM4EADRA2CLMNAADRA2A
SCHEMBL28263575 0.80 KDM4E (0.65) SLC6A4KDM4EADRA2CLMNAADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841263-B2 Macrocyclic compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2014-09-23 US disclosed
US-8841263-B2 Macrocyclic compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2014-09-23 US disclosed
US-8202843-B2 Macrocyclic compounds and methods of making and using the same RIB-X PHARMACEUTICALS, INC. (US) 2012-06-19 US disclosed
US-8202843-B2 Macrocyclic compounds and methods of making and using the same RIB-X PHARMACEUTICALS, INC. (US) 2012-06-19 US disclosed
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2008-02-21 US disclosed
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2008-02-21 US disclosed
US-7291744-B2 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same VIP, PROKR1, PGC SLC6A4 3275/4885KDM4E 4582/4885ADRA2C 3526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.